SLAS Discovery Call for Papers
Advancement of diverse RNA-targeting modalities
A special issue in SLAS Discovery – abstracts accepted until January 15, 2023!
SUBMIT ABSTRACT
SLAS Discovery Guest Editor(s) Matthew Disney, PhD (The Scripps Research Institute) and Helen Lightfoot, PhD (AstraZeneca) invite the submission of abstracts covering topics around the identification and optimization of RNA targeting modalities for publication in a 2023 Special Issue. Manuscript abstracts will be used to select and invite papers for review and publication consideration.
SLAS Discovery seeks high-quality, short- or full-length research reports, reviews, protocols and perspectives related to discovery phase identification and scale profiling of modalities targeting RNA. Manuscripts are welcome from academia, industry, and vendors. All submitted papers will be subject to peer-review to ensure scientific rigor, clarity of expression and integration with other contributions in the SLAS Discovery Special Issue.
Areas of particular interest include, but are not limited to:
- Screening platforms identifying small molecules targeting RNA (smRNA)
- Data analysis and/or computational protocols for smRNA high-throughput screening data including chemistry deep learning and AI approaches
- RNA kinetics, dynamics and modifications, and their application for smRNA drug discovery
- Approaches for identification of smRNA targets
- smRNA target engagement approaches
- Translational investigations between smRNA in vitro and in cell hit identification/validation approaches
- Secondary Pharmacology (screening – wet lab or virtual) investigations into smRNA
- Methods for identification and validation (preclinical and/or clinical) of direct smRNA targeting relevant biomarkers
- Structure-guided approaches to smRNA directed drug discovery including computational methodologies as well as experimental techniques
- Approaches for identification and optimization of RNA degraders (i.e. RIBOTACS)
- High-content RNA directed methodologies
- Examples of successful smRNA and RNA degrader drug discovery efforts and challenges
- Screening platforms identifying oligonucleotides targeting RNA
- Structure-directed off-target evaluations of oligonucleotides targeting RNA
- Approaches to identify and optimize small molecules which modulate proteins directly involved in RNA processing (for example, RNA methylation, adenylation, uridylation).
Submit your abstract before January 15, 2023
High-Content Imaging and Informatics: 3rd Annual Joint Special Issue with the Society for Biomolecular Imaging and Informatics
A special issue in SLAS Discovery – Manuscript abstracts accepted until December 15, 2022!
SUBMIT PROPOSAL
Every year, the societies of SLAS and SBI2 publish a special collaborative issue. The series covers a diverse set of topics, always highlighting the latest advances in high-content imaging and informatics. SLAS Discovery Guest Editors, Judi Wardwell (In Sphero), Gregory Way (University of Colorado) and SBI2 President Neil Carragher (University of Edinburgh) invite the submission of abstracts aligned with the topics of the SBI2 Biomolecular Imaging and Informatics annual meeting for publication in a 2023 Special Issue. Manuscript proposals abstracts will be used to select and invite papers for publication consideration.
The editors seek high-quality research reports, reviews and perspectives to distribute at the 10th annual SBI2 meeting on Biomolecular Imaging and Informatics (September 2023).
Areas of particular interest include, but are not limited to:
- Spatial image-omics and integration with data analysis tools.
- Methods/descriptions supporting AI/ML analysis of images.
- Perspectives on advances in high-content imaging assays.
- Commentary on enhancing translatability of in vitro assays: imaging 3D, co-culture and organ-on-a-chip models.
Submit your abstract before December 15, 2022. Submissions should include your name, contact information, affiliation, a working title, and abstract (250-500 words) as an MS Word document.
Abstract submissions are welcome from academia, industry and exhibitors.
All submitted manuscripts will be subject to peer-review to ensure scientific rigor, clarity of expression and integration with the scope of the special issue. Submissions from SLAS members, non-members and especially attendees of the SBI2 High Content Meeting 2022 are welcomed!
Questions? Please e-mail publishing@slas.org or call +1.630.256.7527, ext. 106.
Call for Papers: Protease Drug Discovery
Completed Manuscripts accepted until October 31!
SUBMIT PROTEASE MANUSCRIPT
SLAS Discovery Guest Editors Jon Ellery, Ph.D. and Nicholas Bland, Ph.D., invite the submission of manuscripts on topics around protease drug discovery for publication in a 2023 Special Issue.
Drs. Ellery and Bland seek high-quality, short- or full-length research reports, reviews and perspectives related to any aspect of the development of therapeutics directed towards proteases. Abstracts are welcome from academia, industry, and vendors.
Areas of particular interest include, but are not limited to:
- Protease kinetics and its application to protease drug discovery, including approaches such as single-molecule kinetics.
- Moving beyond activity assays, for example by utilizing approaches such as biophysics (SPR, GCI, MST, second harmonic generation, etc.) for hit identification, characterization and small molecule optimization for targeting proteases.
- New approaches to enzyme directed therapeutics, including modulating non-enzymatic functions of proteases, enzyme activation, biologics, PROTACs, etc.
- Structure-guided approaches to protease directed drug discovery including computational methodologies as well as experimental techniques including but not limited to X-ray crystallography, NMR and cryo-EM.
- Examples of successful protease drug discovery efforts that forge a path into new therapeutic areas and what innovations were used to make this happen.
- Perspectives on the developing landscape of protease drug discovery and the key challenges that are limiting our ability to bring effective therapeutics to the clinic.
Manuscripts selected for invitation will need to be completed and submitted by August 15. All submitted papers will be subject to peer-review to ensure scientific rigor, clarity of expression and integration with other contributions in the SLAS Discovery Special Issue.
Publication note: After submissions are accepted, articles publish online ahead-of-print within 30 days, becoming immediately searchable and citable with a DOI.
Questions? Please e-mail ajump@slas.org or call +1.630.256.7527, ext. 106.
